Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 8/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.54 |
| ▸ | MGLL | Q99685 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13398520 | 1.00 | KDM1A (0.61) | KDM1AKMT2AMEN1ALDH1A1PKM | |
| SCHEMBL3314080 | 0.91 | ALDH1A1 (0.54) | KDM1AKMT2AMEN1ALDH1A1PKM | |
| SCHEMBL3314069 | 0.91 | ALDH1A1 (0.54) | KDM1AKMT2AMEN1ALDH1A1PKM | |
| SCHEMBL17277458 | 0.90 | KMT2A (0.69) | KDM1AKMT2AMEN1ALDH1A1PKM | |
| SCHEMBL17888327 | 0.86 | PKM (0.59) | KDM1AKMT2AMEN1ALDH1A1PKM | |
| SCHEMBL11918328 | 0.85 | KMT2A (0.62) | KDM1AKMT2AMEN1ALDH1A1PKM | |
| SCHEMBL25975215 | 0.85 | KMT2A (0.62) | KDM1AKMT2AMEN1ALDH1A1PKM | |
| SCHEMBL15764973 | 0.85 | KMT2A (0.62) | KDM1AKMT2AMEN1ALDH1A1PKM | |
| SCHEMBL5386665 | 0.84 | NPC1 (0.61) | KMT2AMEN1ALDH1A1HSD11B1MGLL | |
| SCHEMBL14275540 | 0.84 | HSD17B10 (0.61) | KMT2AMEN1ALDH1A1HSD11B1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332509-B2 | Heterocyclic amides, a process for their preparation, compositions comprising them and their use | MERIAL LIMITED (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332509-B2 | Heterocyclic amides, a process for their preparation, compositions comprising them and their use | MERIAL LIMITED (US) | 2008-02-19 | — | — | US | disclosed |
| US-20060270847-A1 | Process for producing nitrogenous heterocyclic compound | TORAY FINE CHEMICALS CO., LTD. (JP) | 2006-11-30 | — | — | US | disclosed |
| EP-1640364-A1 | PROCESS FOR PRODUCING NITROGENOUS HETEROCYCLIC COMPOUND | Toray Fine Chemicals Co., Ltd. (JP) | 2006-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270847-A1 | Process for producing nitrogenous heterocyclic compound | HNMT, HRH4, QDPR | KDM1A 3779/4885KMT2A 3416/4885MEN1 3106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.